Skip to search formSkip to main contentSkip to account menu

Benlysta

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

belimumab
belimumab 120 MG Injection [Benlysta]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Challenges in the Development of drugs for Systemic Lupus Erythematosus: A Regulatory Perspective
Systemic lupus erythematosus (SLE) is a debilitating disease that affects at least 5 million people worldwide. Currently, there… 
2014
2014
Un lupus discoïde sévère efficacement traité par bélimumab (Benlysta
2013
2013
Belimumab (Benlysta®) per al tractament del lupus eritematós sistèmic
2013
2013
THU0271 Favorable Clinical Response to Belimumab at Three Months
Background Belimumab (Benlysta) is a human monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE… 
2013
2013
AB0615 Favorable response to belimumab seen at three months
Background Belimumab (Benlysta) is a monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE disease… 
2011
2011
Rituximab Seems Safe in RA Lung Disease
2011
2011
FDA to act on benlysta, rare new drug for lupus.
Review
2011
Review
2011
Targeted therapies in systemic lupus erythematosus: successes, failures and future
Purpose The author's goal is to review recent phase III clinical trials in patients with systemic lupus erythematosus (SLE), with… 
2011
2011
FDA Actions in Brief April 2011 (Benlysta, Yervoy, Zostavax, Banzel Oral Suspension, Intuniv, Promacta, Gadavist)
Recent FDA Approvals (through March 2011) related to Benlysta, Yervoy, Zostavax, Banzel Oral Suspension, Intuniv, Promacta… 
2011
2011
Belimumab intravenous injection (Benlysta): IV injection for the treatment of adult patients with active autoantibody-positive systemic lupus erythematosus already receiving standard therapy
New biologic: Belimumab intravenous injection is a B-lymphocyte stimulator-specific inhibitor approved by FDA to treat systemic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)